Medicus 2014;23(2):117-126
126
Prim. dr. sc. Diana Butković, dr. med.
Klinika za dječje bolesti Zagreb,
10000 Zagreb, Klaićeva 16
e-mail:
11. 11. 2013.
20. 1. 2014.
ADRESA ZA DOPISIVANJE:
PRIMLJENO/RECEIVED:
PRIHVAĆENO/ACCEPTED:
acetaminophen and methotrexate by mass spectrometry-based meta-
bolomics.JApplToxicol2012;32:505–20.
38. FukuharaK,OhnoA,AndoY,YamotoT,OkudaH.A1HNMR-basedme-
tabolomics approach for mechanistic insight into acetaminophen-in-
ducedhepatotoxicity.DrugMetabPharmacokinet2011;26:399–406.
39. Sun J, Schnackenberg LK, Beger RD. Studies of acetaminophen
and metabolite in urine and their correlations with toxicity using
metabolomics. Drug Metab Lett 2009;3:130–6.
40. JianW,YaoM,ZhangD,ZhuM.Rapiddetectionandcharacterizationof
theinvitroandurinaryN-acetyl-L-cysteineconjugatesusingquadrupo-
le-linear ion trapmass spectrometry and polarity switching. ChemRes
Toxicol2009;22:1246–55.
41. Loo RL, Coen M, Ebbels T i sur. Metabolic profiling and population
screening of analgesic usage in nuclear magnetic resonance spectros-
copy-basedlarge-scaleepidemiologicstudies.AnalChem2009;81:5119–
29.
42. Winnike JH, Li Z, Wright FA, Macdonald JM, O’Connell TM, Watkins
PB. Use of pharmaco-metabonomics for early prediction of aceta-
minophen-induced hepatotoxicity in humans. Clin Pharmacol Ther
2010;88:45–51.
43. Flores-PérezC,Chávez-PachecoJL,Ramírez-MendiolaBisur.Areliable
method of liquid chromatography for the quantification of acetami-
nophen and identification of its toxic metabolite N-acetyl-p-benzoqu-
inoneimine for application in pediatric studies. Biomed Chromatogr
2011;25:760–6.
44. CălinescuO,BadeaIA,VlădescuL,MeltzerV,PincuE.HPLCseparation
ofacetaminophenanditsimpuritiesusingamixed-modereversed-pha-
se/cationexchangestationaryphase.JChromatogrSci2012;50:335–42.
45. Sun J, Schnackenberg LK, Holland RD i sur. Metabonomics evaluati-
on of urine from rats given acute and chronic doses of acetaminophen
usingNMRandUPLC/MS.JChromatogrBAnalytTechnolBiomedLife
Sci2008;871:328–40.
46. Schnackenberg LK, Chen M, Sun J i sur. Evaluations of the trans-sul-
furation pathway in multiple liver toxicity studies. Toxicol Appl Phar-
macol2009;235:25–32.
47. Preissner S, Kroll K, Dunkel M i sur. SuperCYP: a comprehensive data-
baseonCytochromeP450enzymesincludingatoolforanalysisofCYP-
druginteractions.NucleicAcidsRes2010;38:D237–43.
48. El-Haj B, Al-Amri A, Ali H. Gas chromatography–mass spectrometry
designation and prediction of metabolic dealkylation and hydroxyla-
tion reactions in xenobiotics exemplified by tramadol. J Anal Toxicol
2009;33:34–40.
49. Um SY, Chung MW, Kim KB i sur. Pattern recognition analysis for the
prediction of adverse effects by nonsteroidal anti-inflammatory drugs
using 1HNMR-based metabolomics in rats. Anal Chem 2009;81:4734–
41.
50. HullettB,SalmanS,O’HalloranSJ,PeirceDB,DaviesKM,IlettKF.Deve-
lopment of a population pharmacokinetic model for parecoxib and its
active metabolite valdecoxib after parenteral parecoxib administration
inchildren.Anesthesiology2012;116:1124–33.
51. Zaretzki J, Rydberg P, Bergeron C, Bennett KP, Olsen L, Breneman CM.
RS- Predictor models augmented with SMARTCyp reactivities: robust
metabolic regioselectivity predictions for nine CYP isozymes. J Chem
InfModel2012;52:1637–59.
52. Cregg R, Russo G, Gubbay A, Branford R, Sato H. Pharmacogenetics of
analgesicdrugs.BritishJournalofPainNovember2013;7:189–208.
Jakobović J.
